LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
27/07/2026
Voltar para busca
Dado oficial do USPTO
ONCOSIGNATURE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
27/07/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
22/09/2017
Data de registro
09/04/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/02/2026
Última transação
27/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
Watertown Massachusetts, US
Examinador
CORWIN, CHARLOTTE K
Localização atual
Historical data usage
Descrição da marca
The mark consists of the stylized wording "ONCOSIGNATURE" with "ONCO" in orange and "SIGNATURE" in blue. Above the wording are two interlocked circles, each consisting of an outer border of small blue circles and an inner layer of larger orange circles.
Titulares e representantes
Titulares
Acrivon Therapeutics Inc.
OncoSignature AB
Representantes
Sara M. Bauer Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; medical preparations for use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; veterinary pharmaceutical preparations for use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; pharmaceutical and medical preparations for treatmentprevention and alleviation of cancer; pharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; biological preparations for medical and veterinary purposesfor use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testingspecifically in oncology and premalignant disorders and benign tumors; chemical preparations for therapeutic usefor pharmaceutical or medical purposesfor use in oncologyspecifically the preventionalleviation and treatment of cancer and precancerous diseases and benign tumors; reagents for medical usefor medical diagnosisdrug-tailored efficacy prediction and/or analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits and does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposes
Classe 42
Scientific and technological research and consultation servicesin the medical * and pharmaceutical research fields of drug-tailoredefficacy-predictive biomarkerspharmacodynamic biomarkerspatient responder identificationindication finding * pharmaceuticalscientific research fields of drug-tailoredefficacy-predictive biomarkerspharmacodynamic biomarkersdrug repurposingidentification of rational drug combinations ; industrial analysis and research servicesindustrial research in the field of oncology * biomarkers and predictive modeling; * basic medical research and medical clinical researchhereunder for development of therapeutics * using biomarkers and predictive modeling; * drug discovery services * in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkerspatient responder identificationpharmacodynamic biomarkers and indication finding; * consultancy in the field of pharmaceutical research and development * services in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkerspatient responder identificationpharmacodynamic biomarkers and indication finding; * medical and scientific research related to cancer and cancer therapyincluding research related to treatmentprevention and alleviation of cancer * in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkspatient responder identificationpharmacodynamic biomarkers and indication finding; * pharmaceutical research services related to prediction of drug treatment efficacy * using biomarkers and predictive modeling; * medical research services related to cancer diagnosiscancer prognosis and drug-tailored efficacy prediction * using biomarkers and predictive modeling; * medical researchanalysis related to cancer diagnosiscancer prognosis and drug-tailored efficacy prediction * using biomarkers and predictive modeling *
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
24/07/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/07/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
10/02/2026
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
10/02/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/02/2026
ES71
TEAS SECTION 71 RECEIVED
07/10/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
18/04/2025
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
12/03/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/10/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
09/04/2024
CHLD
CHANGE OF OWNER RECEIVED FROM IB
26/02/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
13/07/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/07/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
13/07/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/07/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/07/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
13/07/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/08/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
31/07/2019
FIMP
FINAL DISPOSITION PROCESSED
31/07/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/07/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
09/04/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/01/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/01/2019
GPNX
NOTIFICATION PROCESSED BY IB
25/01/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/01/2019
PUBO
PUBLISHED FOR OPPOSITION
22/01/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/01/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/01/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/01/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/12/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
13/12/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
13/12/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
13/12/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
13/12/2018
DOCK
ASSIGNED TO EXAMINER
27/08/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/08/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/08/2018
ALIE
ASSIGNED TO LIE
02/08/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/07/2018
RFNT
REFUSAL PROCESSED BY IB
03/02/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/01/2018
RFRR
REFUSAL PROCESSED BY MPU
18/01/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/01/2018
MAFR
APPLICATION FILING RECEIPT MAILED
06/01/2018
CNRT
NON-FINAL ACTION WRITTEN
05/01/2018
DOCK
ASSIGNED TO EXAMINER
02/01/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/01/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
28/12/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ONCOSIGNATURE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.